Drug intelligence / Profile preview

YOVIS

Development stage
Unknown
Lead developer
Alfasigma
Modality
Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration
Oral
01

Overview

YOVIS is a **food supplement containing a proprietary mix of live probiotics**, formulated as capsules or granules for oral use[1][3][4][5][6][9]. The active ingredients are freeze-dried live lactic ferments including bifidobacteria (Bifidobacterium shortum, Bifidobacterium infantis, Bifidobacterium longum), streptococci (Streptococcus salivarius subsp. thermophilus), and lactobacilli (Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus faecium)[4][5]. Its **primary mechanism** is probiotic action: these strains help restore intestinal flora balance, combat pathogenic bacteria, stimulate immune response, produce vitamins (e.g., Vitamin B, Vitamin K), and prevent or alleviate gastrointestinal disturbances such as antibiotic-associated diarrhea, acute diarrhea, irritable bowel syndrome, and intestinal dysmicrobial syndromes[3][4][5]. YOVIS is not a pharmaceutical drug but a commercial food supplement, is lactose-free and gluten-free, and can be used by diabetics, coeliacs, and lactose-intolerant individuals[4]. It is marketed primarily for the **prevention and treatment of acute or antibiotic-associated diarrhea** and for improved gastrointestinal health[1][3][4][5].

Brand names
YOVIS
Other names
YOVIS

Beyond the preview

Go deeper on YOVIS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on YOVIS.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call